A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral Anaplastic Lymphoma Kinase (ALK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Brigatinib (AP26113)
A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral ALK/EGFR Inhibitor AP26113
Sponsor: Ariad Pharmaceuticals
Listed as NCT01449461, this PHASE1/PHASE2 trial focuses on Carcinoma, Non-Small-Cell Lung and Lymphoma, Large-Cell, Anaplastic and remains completed. Sponsored by Ariad Pharmaceuticals, it has been updated 11 times since 2011, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Sep 2021 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Jan 2021 — Sep 2021 [monthly]
Completed PHASE1_PHASE2
-
Apr 2020 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
Status: Active Not Recruiting → Completed
▶ Show 6 earlier versions
-
Dec 2019 — Apr 2020 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Aug 2019 — Dec 2019 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Jun 2018 — Aug 2019 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Aug 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Unknown Status → Active Not Recruiting
-
Feb 2017 — Aug 2017 [monthly]
Unknown Status PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Unknown Status PHASE1_PHASE2
First recorded
Sep 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Ariad Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.